-
KaloBios Signs Definitive Agreement with Martin Shkreli Regarding Ownership of Shares
-
KaloBios (KBIOQ) Completes Chapter 11 Bankruptcy; Acquires Benznidazole Development Rights
-
KaloBios Emerges from Chapter 11 Bankruptcy
-
KaloBios CEO to Present at the International Society for Neglected Tropical Diseases Conference
-
KaloBios Pharmaceuticals (KBIOQ) Announces New Pricing Model
-
KaloBios Announces New Product Pricing Model
-
Ex-drug executive Shkreli has $40 million trading loss: U.S.

